Emergent BioSolutions secures Sanofi unit for up to $125M
July 17, 2017
Drug Discovery | Paris, France | Corporate Acquisition
Emergent BioSolutions has agreed to acquire Sanofi's smallpox vaccine business for an upfront payment of $97.5 million, as well as up to $27.5 million in regulatory- and manufacturing-related targets. The transaction includes the unit's 10-year contract supplying the US Centers for Disease Control and Prevention, which has a remaining value of up to approximately $160 million.